{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:15:39Z","timestamp":1790270139624,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Carbohydrate Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.carres.2025.109545","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:04:04Z","timestamp":1748531044000},"page":"109545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Recent advances on the syntheses of oligosaccharides and the corresponding glycoconjugates towards development of vaccine candidates against invasive Neisseria meningitidis strains"],"prefix":"10.1016","volume":"555","author":[{"given":"Nabamita","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana Mohan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6506-5089","authenticated-orcid":false,"given":"Rina","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carres.2025.109545_bib1a","article-title":"Molecular medical microbiology","author":"Spearman","year":"2024"},{"key":"10.1016\/j.carres.2025.109545_bib1b","doi-asserted-by":"crossref","unstructured":"N. E. Rosenstein, B. A. Perkins, D. D. Stephens, T Popovic, J. M. Hughes, Meningococcal disease, N. Engl. J. Med. 344 (2001) 1378-1388. doi: 10.1056\/NEJM200105033441807.","DOI":"10.1056\/NEJM200105033441807"},{"key":"10.1016\/j.carres.2025.109545_bib2","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitides","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.carres.2025.109545_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2017.04.007","article-title":"Meningococcal disease in the middle East and Africa: findings and updates from the global meningococcal initiative","volume":"75","author":"Borrow","year":"2017","journal-title":"J. Infect."},{"key":"10.1016\/j.carres.2025.109545_bib4","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(06)68141-5","article-title":"Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China","volume":"367","author":"Shao","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.carres.2025.109545_bib6a","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1128\/JCM.00091-09","article-title":"Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002","volume":"47","author":"Whitney","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.carres.2025.109545_bib6b","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12889-022-12795-9","article-title":"Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature","volume":"22","author":"Guedes","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.carres.2025.109545_bib7a","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3201\/eid0805.010227","article-title":"Clonal groupings in serogroup X Neisseria meningitidis","volume":"8","author":"Gagneux","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib7b","first-page":"2852","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013"},{"key":"10.1016\/j.carres.2025.109545_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019513","article-title":"Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso","volume":"6","author":"Delrieu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.carres.2025.109545_bib10","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib11a","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.330.6010.1466","article-title":"The Beginning of the end for Africa's devastating meningitis outbreaks?","volume":"330","author":"Roberts","year":"2010","journal-title":"Sciences"},{"key":"10.1016\/j.carres.2025.109545_bib11b","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","volume":"364","author":"Sow","year":"2011","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.carres.2025.109545_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib13a","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1093\/clinids\/24.Supplement_1.S98","article-title":"Antibiotic resistance in Neisseria meningitidis","volume":"24","author":"Oppenheim","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib13b","unstructured":"Antimicrobial resistance, https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6924a2.htm."},{"key":"10.1016\/j.carres.2025.109545_bib13c","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260677","article-title":"Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010\/11 to 2018\/19)","volume":"16","author":"Willerton","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.carres.2025.109545_bib13d","article-title":"Penicillin- and ciprofloxacin-resistant invasive Neisseria meningitidis isolates from Japan","volume":"10","author":"Saito","year":"2022","journal-title":"Microbial Spectrum Obs"},{"key":"10.1016\/j.carres.2025.109545_bib14a","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.carres.2025.109545_bib14b","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1128\/iai.34.3.725-732.1981","article-title":"Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults","volume":"34","author":"Griffiss","year":"1981","journal-title":"Infect. Immun."},{"key":"10.1016\/j.carres.2025.109545_bib15a","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/chem.201603599","article-title":"An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity","volume":"23","author":"Khatun","year":"2017","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.carres.2025.109545_bib15b","unstructured":"NeisVac-C\u00ae vaccine (Meningococcal group C-TT conjugate vaccine, adsorbed)- Pfizer, https:\/\/www.pfizer.ca\/en\/our-products\/neisvac-c-meningococcal-group-c-tt-conjugate-vaccine-adsorbed."},{"key":"10.1016\/j.carres.2025.109545_bib15c","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40121-019-0254-1","article-title":"Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review","volume":"8","author":"Presa","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.carres.2025.109545_bib15d","first-page":"2205","article-title":"Findlow, Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines, Hum. Vaccin. Immunother","volume":"17","author":"Serra","year":"2021"},{"issue":"122","key":"10.1016\/j.carres.2025.109545_bib15e","first-page":"15672","article-title":"Adamo, Synthetic glycans to improve current glycoconjugate vaccines and fight antimicrobial resistance, Chem. Rev","volume":"20","author":"L.Del Bino","year":"2022"},{"key":"10.1016\/j.carres.2025.109545_bib15f","author":"P"},{"key":"10.1016\/j.carres.2025.109545_bib15g","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122689","article-title":"Glycoconjugates: advances in modern medicines and human health","volume":"348","author":"Chettri","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.carres.2025.109545_bib15h","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40121-020-00393-4","article-title":"Post-marketing surveillance observational study of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-DT, MCV4\/Menactra\u00ae) in the Republic of Korea, 2014\u20132019","volume":"10","author":"Kim","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.carres.2025.109545_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37757\/MR2007V9.N1.6","article-title":"Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application","volume":"9","author":"Sotolongo","year":"2007","journal-title":"MEDICC Rev"},{"key":"10.1016\/j.carres.2025.109545_bib17a","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00566-16","article-title":"Recent progress in the prevention of serogroup B meningococcal disease","volume":"24","author":"Feavers","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.carres.2025.109545_bib17b","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/infdis\/jix446","article-title":"Oregon meningococcal carriage T meningococcal carriage following A vaccination campaign with MenB-4C and MenB-FHbp in response to a University serogroup B meningococcal disease outbreak-Oregon, 2015\u20132016","volume":"216","author":"McNamara","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib17c","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14760584.2018.1483726","article-title":"From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine","volume":"17","author":"Perez","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.carres.2025.109545_bib18a","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1039\/a809773i","article-title":"Recent developments in glycoconjugates","volume":"1","author":"Davis","year":"1999","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.carres.2025.109545_bib18b","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.carres.2025.109545_bib18c","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14760584.2020.1775077","article-title":"Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production","volume":"19","author":"Dow","year":"2020","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.carres.2025.109545_bib19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/adc.2007.136036","article-title":"A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial","volume":"93","author":"Pace","year":"2008","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.carres.2025.109545_bib20a","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40121-022-00609-9","article-title":"Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review","volume":"11","author":"Marshall","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.carres.2025.109545_bib20b","unstructured":"M. La Force, Progress on MenACWYX vaccine: Phase 1 trial results, MRF Conference. https:\/\/www.meningitis.org\/mrf-conference-2017."},{"key":"10.1016\/j.carres.2025.109545_bib21","first-page":"401","article-title":"Neisseria meningitidis lipopolysaccharides in human pathology","volume":"7","author":"Brandtzaeg","year":"2001","journal-title":"J. Endotoxin Res."},{"key":"10.1016\/j.carres.2025.109545_bib22","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0731-7085(02)00462-4","article-title":"Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture","volume":"30","author":"Jones","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.carres.2025.109545_bib23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0731-7085(02)00462-4","article-title":"Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture","volume":"30","author":"Jones","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.carres.2025.109545_bib24","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0021-9258(19)41784-5","article-title":"Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance","volume":"250","author":"Bhattacharjee","year":"1975","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/o76-001","article-title":"Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO1","volume":"54","author":"Bhattacharjee","year":"1976","journal-title":"Can. J. Biochem."},{"key":"10.1016\/j.carres.2025.109545_bib26","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1016\/j.vaccine.2012.07.032","article-title":"Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies","volume":"30","author":"Xie","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib27a","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1751-7915.2010.00178.x","article-title":"Vaccine development against Neisseria meningitidis","volume":"4","author":"Vogel","year":"2011","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.carres.2025.109545_bib27b","first-page":"ftx033","article-title":"Novel approaches to Neisseria meningitidis vaccine design","volume":"75","author":"Christodoulides","year":"2017","journal-title":"Pathogens Dis"},{"key":"10.1016\/j.carres.2025.109545_bib27c","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines6010012","article-title":"Meningococcal vaccines: current status and emerging strategies","volume":"6","author":"McCarthy","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.carres.2025.109545_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10719-021-09990-y","article-title":"Carbohydrate based meningococcal vaccines: past and present overview","volume":"38","author":"Berti","year":"2021","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.carres.2025.109545_bib29a","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1002\/1521-3765(20021004)8:19<4424::AID-CHEM4424>3.0.CO;2-1","article-title":"Towards a synthetic glycoconjugate vaccine against Neisseria meningitidis","volume":"8","author":"Berkin","year":"2002","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.carres.2025.109545_bib29b","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1039\/b507898a","article-title":"Synthesis of structures corresponding to the capsular polysaccharide of Neisseria meningitidis group A","volume":"3","author":"Sl\u00e4tteg\u00e5rd","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib29c","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1039\/C7QO00468K","article-title":"Synthesis and immunochemical evaluation of a novel: Neisseria meningitidis serogroup A tetrasaccharide and its conjugate","volume":"4","author":"Harale","year":"2017","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.carres.2025.109545_bib27d","first-page":"228","article-title":"Biopolymer fragments, containing glycosylphosphate residues. 12. Synthesis of glycosylphosphosugars, containing 2-acetamido-2-deoxy-alpha-D-mannopyranosylphosphate residues including a fragment of the Neisseria meningitidis A capsule antigen","volume":"19","author":"Utkina","year":"1993","journal-title":"Bioorg. Khim."},{"key":"10.1016\/j.carres.2025.109545_bib30","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.vaccine.2012.08.021","article-title":"Relative stability of meningococcal serogroup A and X polysaccharides","volume":"30","author":"Berti","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib31","first-page":"123","article-title":"Production and control of Neisseria meningitidis vaccines","volume":"13","author":"Frasch","year":"1990","journal-title":"Biotechnol. Processes"},{"key":"10.1016\/j.carres.2025.109545_bib32","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1021\/jo9519468","article-title":"Stereoselective synthesis of the isosteric phosphono analogues of N-acetyl-\u03b1-d-glucosamine 1- phosphate and N-acetyl-\u03b1-d-mannosamine 1-phosphate","volume":"61","author":"Casero","year":"1996","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib33","first-page":"1147","article-title":"Synthesis of the phosphono analogue of the dimeric subunit of Neisseria meningitidis type a capsular polysaccharide","volume":"7","author":"Torres-S\u00e1nchez","year":"2005","journal-title":"Synlett"},{"key":"10.1016\/j.carres.2025.109545_bib34","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1039\/B614038F","article-title":"Synthesis of stable C-phosphonate analogues of Neisseria meningitidis group a capsular polysaccharide structures using modified Mitsunobu reaction conditions","volume":"4","author":"Teodorovi\u0107","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib35","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1002\/chem.200601743","article-title":"Synthesis and biological evaluation of phosphono analogues of capsular polysaccharide fragments from Neisseria meningitidis A","volume":"13","author":"Torres-S\u00e1nchez","year":"2007","journal-title":"Chem.\u2212Eur. J."},{"key":"10.1016\/j.carres.2025.109545_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.carres.2007.10.015","article-title":"Preparation of glycoconjugates by dialkyl squarate chemistry revisited","volume":"343","author":"Hou","year":"2008","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.carres.2025.109545_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acsinfecdis.5b00071","article-title":"A synthetic disaccharide analogue from Neisseria meningitidis A capsular polysaccharide stimulates immune cell responses and induces immunoglobulin G (IgG) production in mice when protein-conjugated","volume":"1","author":"Fallarini","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib38","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1039\/b907000a","article-title":"Modeling of synthetic phosphono and carba analogues of N-acetyl-\u03b1-d-mannosamine 1-phosphate, the repeating unit of the capsular polysaccharide from Neisseria meningitidis serovar A","volume":"7","author":"Toma","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib39","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1039\/c2ob25222h","article-title":"Synthesis and preliminary biological evaluation of carba analogues from Neisseria meningitidis A capsular polysaccharide","volume":"10","author":"Gao","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib40","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1021\/cb400463u","article-title":"Immunoactivity of protein conjugates of carba analogues from Neisseria meningitidis A capsular polysaccharide","volume":"8","author":"Gao","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.carres.2025.109545_bib41","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0040-4039(01)90461-7","article-title":"Deoxynucleoside phosphoramidites\u2014a new class of key intermediates for deoxypolynucleotide synthesis","volume":"22","author":"Beaucage","year":"1981","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.carres.2025.109545_bib42","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1038\/s41467-020-18279-x","article-title":"A stabilized glycomimetic conjugate vaccine inducing protective antibodies against Neisseria meningitidis serogroup A","volume":"11","author":"Enotarpi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.carres.2025.109545_bib43","doi-asserted-by":"crossref","first-page":"29795","DOI":"10.1073\/pnas.2011385117","article-title":"Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide","volume":"117","author":"Henriques","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.carres.2025.109545_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"322","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.carres.2025.109545_bib45a","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0140-6736(84)91083-3","article-title":"Safety of vaccines containing meningococcal group B polysaccharide","volume":"324","author":"Zollinger","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.carres.2025.109545_bib45b","first-page":"17871","volume":"108","author":"Robbins","year":"2011"},{"key":"10.1016\/j.carres.2025.109545_bib46a","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningo-coccal serogroup B panel confirms that MATS underestimates 4CMenB vac-cine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib46b","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/14760584.2018.1547637","article-title":"Meningococcal B vaccine (4CMenB): the journey from research to real world experience","volume":"17","author":"Rappuoli","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.carres.2025.109545_bib47","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib48","first-page":"3","article-title":"Isolation and characterization of lipopolysaccharides","volume":"vol. 431","author":"Apicella","year":"2008"},{"key":"10.1016\/j.carres.2025.109545_bib49a","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/14760584.2021.1984889","article-title":"Recent advances in lipopolysaccharide-based glycoconjugate vaccines","volume":"20","author":"Zhu","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.carres.2025.109545_bib49b","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10719-013-9500-z","article-title":"Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: conjugates based on core oligosaccharides","volume":"31","author":"St Michael","year":"2014","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.carres.2025.109545_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chembiol.2014.11.016","article-title":"Antigenic potential of a highly conserved Neisseria meningitidis lipopolysaccharide inner core structure defined by chemical synthesis","volume":"22","author":"Reinhardt","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.carres.2025.109545_bib51","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.carres.2010.03.006","article-title":"Synthesis of phosphorylated 3,4-branched trisaccharides corresponding to LPS inner core structures of Neisseria meningitidis and Haemophilus influenza","volume":"345","author":"Olsson","year":"2010","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.carres.2025.109545_bib52","doi-asserted-by":"crossref","first-page":"7780","DOI":"10.1021\/jo9808573","article-title":"Synthesis of a branched heptose- and Kdo-containing common tetrasaccharide core structure of Haemophilus influenzae lipopolysaccharides via a 1,6-anhydro-l-glycero-\u03b2-d-manno-heptopyranose intermediate","volume":"63","author":"Bernlind","year":"1998","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib53","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1021\/ja401164s","article-title":"Diversity-oriented synthesis of inner core oligosaccharides of the lipopolysaccharide of pathogenic Gram-negative bacteria","volume":"135","author":"Yang","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.carres.2025.109545_bib54a","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1039\/C1SC00804H","article-title":"Total synthesis of the core tetrasaccharide of Neisseria meningitidis lipopolysaccharide, a potential vaccine candidate for meningococcal diseases","volume":"3","author":"Yang","year":"2012","journal-title":"Chem. Sci."},{"key":"10.1016\/j.carres.2025.109545_bib54b","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chembiol.2014.11.016","article-title":"Antigenic potential of a highly conserved Neisseria meningitidis lipopolysaccharide inner core structure defined by chemical synthesis","volume":"22","author":"Reinhardt","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.carres.2025.109545_bib55","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2008.09.041","article-title":"Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures","volume":"26","author":"J\u00e4kel","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib56a","doi-asserted-by":"crossref","first-page":"42787","DOI":"10.1074\/jbc.M111.291799","article-title":"Molecular basis of lipopolysaccharide heterogeneity in Escherichia coli: envelope stress-responsive regulators control the incorporation of glycoforms with a third 3-deoxyalpha-D-manno-oct-2-ulosonic acid and rhamnose","volume":"286","author":"Klein","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib56b","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1128\/JB.01459-09","article-title":"Lipopolysaccharide as shield and receptor for R-pyocin-mediated killing in Pseudomonas aeruginosa","volume":"192","author":"Kohler","year":"2010","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.carres.2025.109545_bib57","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.carres.2009.12.015","article-title":"Synthesis of a neoglycoconjugate containing a Chlamydophila psittaci-specific branched Kdo trisaccharide epitope","volume":"345","author":"Kosma","year":"2010","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.carres.2025.109545_bib58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nchem.2432","article-title":"An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2","volume":"8","author":"Kong","year":"2016","journal-title":"Nat. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1139\/m92-116","article-title":"Capsules of Escherichia coli, expression and biological significance","volume":"38","author":"Jann","year":"1992","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/j.carres.2025.109545_bib60","unstructured":"WHO. Situation update on meningitis C epidemic risk, 21 December 2017. http:\/\/www.who.int\/emergencies\/diseases\/meningitis\/meningitis-c-epidemic-risk\/en\/."},{"key":"10.1016\/j.carres.2025.109545_bib61","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1002\/anie.201101794","article-title":"Efficient and stereoselective synthesis of \u03b1-(2\u21929) oligosialic acids: from monomers to dodecamers","volume":"50","author":"Chu","year":"2011","journal-title":"Angew. Chem. Int."},{"key":"10.1016\/j.carres.2025.109545_bib62","doi-asserted-by":"crossref","first-page":"9647","DOI":"10.1039\/C5CC01794G","article-title":"Synthesis and immunological study of a-2,9-oligosialic acid conjugates as anti-group C meningitis vaccines","volume":"51","author":"Liao","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.carres.2025.109545_bib63a","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/S0264-410X(99)00062-6","article-title":"The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1","volume":"17","author":"Moore","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib63b","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.carres.2025.109545_bib63c","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ddtec.2020.11.006","article-title":"Recent advances in self-adjuvanting glycoconjugate vaccines","volume":"37","author":"Manabe","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.carres.2025.109545_bib65","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1039\/C4OB00390J","article-title":"Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers","volume":"12","author":"Zhou","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/acscentsci.5b00364","article-title":"Fully synthetic self-adjuvanting \u03b1-2,9-oligosialic acid based conjugate vaccines against group C Meningitis","volume":"2","author":"Liao","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.carres.2025.109545_bib67","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1021\/jo100824s","article-title":"5-N,4-Ocarbonyl-7,8,9-tri-O-chloroacetyl-protected sialyl donor for the stereoselective synthesis of a-(2\u21929)-tetrasialic acid","volume":"75","author":"Lin","year":"2010","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib68","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1016\/j.vaccine.2019.07.053","article-title":"Development and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Neisseria meningitidis serogroup C","volume":"37","author":"Dalal","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.carres.2025.109545_bib69a","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib69b","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jfluchem.2010.03.003","article-title":"Fluorine in health care: organofluorine containing blockbuster drugs","volume":"131","author":"O'Hagan","year":"2010","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib69c","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib70","doi-asserted-by":"crossref","first-page":"15366","DOI":"10.1021\/jacs.4c03179","article-title":"A fluorinated sialic acid vaccine lead against meningitis B and C","volume":"146","author":"Jordan","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.carres.2025.109545_bib71","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1002\/anie.201812963","article-title":"Stereospecific \u03b1-sialylation by site-selective fluorination","volume":"58","author":"Hayashi","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.carres.2025.109545_bib72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1203\/01.PDR.0000156372.13569.08","article-title":"Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease","volume":"58","author":"Vermont","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.carres.2025.109545_bib73","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/S0140-6736(00)03502-9","article-title":"Serogroup W135 meningococcal disease in Hajj pilgrims","volume":"356","author":"Taha","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.carres.2025.109545_bib74a","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(02)00455-3","article-title":"Chronicle of an outbreak foretold. meningococcal meningitis W135 in Burkina Faso","volume":"2","author":"Decosas","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib74b","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/499822","article-title":"Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002","volume":"193","author":"Raghunathan","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.carres.2025.109545_bib75","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1002\/anie.201302540","article-title":"Synthesis of Neisseria meningitidis serogroup W135 capsular oligosaccharides for immunogenicity comparison and vaccine development","volume":"52","author":"Wang","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.carres.2025.109545_bib76","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1021\/acscatal.9b05597","article-title":"Size-controlled chemoenzymatic synthesis of homogeneous oligosaccharides of Neisseria meningitidis W capsular polysaccharide","volume":"10","author":"Lia","year":"2020","journal-title":"ACS Catal."},{"key":"10.1016\/j.carres.2025.109545_bib77","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/oxfordjournals.aje.a120854","article-title":"Prevalence of meningococcal serogroups and description of three new groups","volume":"87","author":"Evans","year":"1968","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.carres.2025.109545_bib78","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4269\/ajtmh.2009.80.619","article-title":"Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in Western Kenya, 2005\u22122006","volume":"80","author":"Mutonga","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.carres.2025.109545_bib79a","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1046\/j.1469-0691.2003.00685.x","article-title":"Infections by Neisseria meningitidis serogroup X in Spain","volume":"9","author":"del Castillo","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.carres.2025.109545_bib79b","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/00029330-200804010-00017","article-title":"A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China","volume":"7","author":"Chen","year":"2008","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.carres.2025.109545_bib80","doi-asserted-by":"crossref","first-page":"19077","DOI":"10.1073\/pnas.1314476110","article-title":"Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X","volume":"110","author":"Micoli","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.carres.2025.109545_bib81","first-page":"166","article-title":"Synthesis of Neisseria meningitidis X capsular polysaccharide fragments","volume":"2","author":"Morelli","year":"2013","journal-title":"ARKIVOC (Gainesville, FL, U. S.)"},{"key":"10.1016\/j.carres.2025.109545_bib82","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3762\/bjoc.10.247","article-title":"Synthesis and immunological evaluation of protein conjugates of Neisseria meningitidis X capsular polysaccharide fragments","volume":"10","author":"Morelli","year":"2014","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib83","doi-asserted-by":"crossref","first-page":"41332","DOI":"10.1039\/C5RA02993G","article-title":"Synthesis of a tetrasaccharide and its glycoconjugate corresponding to the capsular polysaccharide of Neisseria meningitidis serogroup X and its immunochemical studies","volume":"5","author":"Harale","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.carres.2025.109545_bib84","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/glycob\/cwt102","article-title":"Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development","volume":"24","author":"Fiebig","year":"2014","journal-title":"Glycobiology (Oxf.)"},{"key":"10.1016\/j.carres.2025.109545_bib85","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/acschembio.7b01057","article-title":"Combined chemical synthesis and tailored enzymatic elongation provide fully synthetic and conjugation-ready Neisseria meningitidis serogroup X vaccine antigens","volume":"13","author":"Oldrini","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.carres.2025.109545_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/npjvaccines.2016.17","article-title":"An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate","author":"Fiebig","year":"2016","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.carres.2025.109545_bib87a","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/vaccines9091021","article-title":"Recent and future advances in the chemoenzymatic synthesis of homogeneous glycans for bacterial glycoconjugate vaccine development","volume":"9","author":"Adegbite","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.carres.2025.109545_bib87b","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10719-013-9490-x","article-title":"Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates","volume":"30","author":"McCarthy","year":"2013","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.carres.2025.109545_bib87c","doi-asserted-by":"crossref","first-page":"11718","DOI":"10.1074\/jbc.M113.452276","article-title":"Biochemical and biophysical characterization of the sialyl-\/hexosyltransferase synthesizing the meningococcal serogroup W135 heteropolysaccharide capsule","volume":"288","author":"Romanow","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib87d","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1074\/jbc.RA117.000488","article-title":"Efficient solid-phase synthesis of meningococcal capsular oligosaccharides enables simple and fast chemoenzymatic vaccine production","volume":"293","author":"Fiebig","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib87e","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1021\/acs.joc.0c02134","article-title":"A chemoenzymatic synthon strategy for synthesizing N-acetyl analogs of O-acetylated N. meningitidis W capsular polysaccharide oligosaccharides","volume":"85","author":"Lia","year":"2020","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.carres.2025.109545_bib88","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.46234\/ccdcw2024.249","article-title":"Outbreak reports: the first case of serogroup Y Neisseria meningitidis and an expanded investigation of healthy carriers, Shijiazhuang city, Hebei province, China, 2023","volume":"6","author":"Guo","year":"2024","journal-title":"China CDC Weekly"},{"key":"10.1016\/j.carres.2025.109545_bib89","first-page":"973","article-title":"Statewide outbreak of Neisseria meningitidis serogroup Y, sequence type 1466 \u2014 Virginia, 2022\u20132024. MMWR Morb. Mortal Wkly","volume":"73","author":"Robinson","year":"2024","journal-title":"Rep"},{"key":"10.1016\/j.carres.2025.109545_bib90a","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.1095209","article-title":"A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae Type b","volume":"305","author":"Verez-Bencomo","year":"2004","journal-title":"Sciences"},{"key":"10.1016\/j.carres.2025.109545_bib90b","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/CVI.00144-06","article-title":"Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae Type b in human adult volunteers","volume":"13","author":"Tora\u00f1o","year":"2006","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Carbohydrate Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008621525001715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008621525001715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T08:08:01Z","timestamp":1751962081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008621525001715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":131,"alternative-id":["S0008621525001715"],"URL":"https:\/\/doi.org\/10.1016\/j.carres.2025.109545","relation":{},"ISSN":["0008-6215"],"issn-type":[{"value":"0008-6215","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances on the syntheses of oligosaccharides and the corresponding glycoconjugates towards development of vaccine candidates against invasive Neisseria meningitidis strains","name":"articletitle","label":"Article Title"},{"value":"Carbohydrate Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carres.2025.109545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109545"}}